Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 18/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.42 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.36 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4247782 | 1.00 | DPP4 (0.49) | DPP4CHRM1NPBWR1CCNE2CCNA2 | |
| SCHEMBL4252162 | 0.88 | DPP4 (0.46) | DPP4CHRM1NPBWR1 | |
| SCHEMBL4252710 | 0.86 | DPP4 (0.41) | DPP4CHRM1NPBWR1 | |
| SCHEMBL4252713 | 0.86 | DPP4 (0.41) | DPP4CHRM1NPBWR1 | |
| SCHEMBL4252804 | 0.86 | DPP4 (0.50) | DPP4CHRM1CCNE2CCNA2CCNE1 | |
| SCHEMBL4252811 | 0.86 | DPP4 (0.50) | DPP4CHRM1CCNE2CCNA2CCNE1 | |
| SCHEMBL4248871 | 0.84 | DPP4 (0.67) | DPP4CHRM1NPBWR1 | |
| SCHEMBL4248869 | 0.84 | DPP4 (0.67) | DPP4CHRM1NPBWR1 | |
| SCHEMBL4460766 | 0.84 | DPP4 (0.48) | DPP4 | |
| SCHEMBL4248434 | 0.81 | DPP4 (0.52) | DPP4CHRM1NPBWR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088569-A1 | 2-AMINO-IMIDAZO[4,5-D]PYRIDAZIN-4-ONES, THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | ECKHARDT MATTHIAS | 2009-04-02 | — | — | US | disclosed |
| US-7476671-B2 | 2-amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-13 | — | — | US | disclosed |
| US-20070088038-A1 | 2-AMINO-IMIDAZO[4,5-D]PYRIDAZIN-4-ONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | ECKHARDT MATTHIAS | 2007-04-19 | — | — | US | disclosed |
| US-7179809-B2 | 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-20 | — | — | US | disclosed |
| US-20050234235-A1 | 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234235-A1 | 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions | DPP4, DPP3, DPP8 | DPP4 1/4885CHRM1 497/4885NPBWR1 3478/4885 |
| US-20090088569-A1 | 2-AMINO-IMIDAZO[4,5-D]PYRIDAZIN-4-ONES, THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP3, DPP7 | DPP4 1/4885CHRM1 638/4885NPBWR1 3326/4885 |
| US-20070088038-A1 | 2-AMINO-IMIDAZO[4,5-D]PYRIDAZIN-4-ONES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP3, DPP8 | DPP4 1/4885CHRM1 497/4885NPBWR1 3478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.